ACCESSIBILITY

24/7

Headlines

13:43

Full list of Israeli high-tech layoffs in 2025

13:38

Hydrogen startup Electriq Global collapses under nearly $30M in debt, despite raising $25M

11:26

PwC integrates altshare’s algorithm to streamline startup valuations

14:27

Nice beats Q4 estimates but shares plunge on weak 2025 outlook

Buzz

Most popular

Daily

Weekly

Insight Partners hit by cyber attack with possible data leaks

CyberArk’s surge, Wiz and Cato prepare for IPOs: Israeli cyber firms ready for the next big move

How Intel ruined an Israeli startup it bought for $2B—and lost the AI race

Riskified cuts staff as struggles continue

Techtonic to invest over $140 million to build one of Israel's largest data centers

More news

Teva

20 stories about Teva

לוגו חברת טבע ב מטה החברה ב תל אביב 20.2.24

Teva signals return to fundraising after decade-long crisis

08.02.25|Sophie Shulman

Israeli pharmaceutical giant eyes stock offering as part of its recovery plan.

Teva’s stock surge comes to a halt, falling 14% amid weak 2025 outlook

30.01.25|Sophie Shulman

Despite a strong 80% gain in 2024, Teva’s stock dropped after the company revealed disappointing profitability and cash flow forecasts.

Teva surpasses expectations in Q4 but sets cautious outlook for 2025

29.01.25|Sophie Shulman

Despite a strong finish to the year, Teva forecasts lower-than-expected earnings and revenue growth for 2025.

Teva’s 10-year turnaround takes shape with stunning trial results

18.12.24|Sophie Shulman

Duvakitug signals a brighter future for the Israeli pharma giant.

מפגש עיתונאים ראשון עם נשיא ומנכל חברת טבע ריצ'רד פרנסיס

Teva shares jump as its most promising drug shows exceptional trial results

17.12.24|Sophie Shulman

Duvakitug, designed to treat colitis and Crohn’s disease, exceeded expectations and positions Teva to compete in the $28 billion global market for inflammatory bowel disease treatments.

How dual-listed companies boost profits without earning more

08.12.24|Uri Tal Tenne

The creative accounting tricks Israeli firms use to inflate earnings.

Immunai and Teva launch multi-tear AI collaboration for smarter drug development

14.11.24|CTech

The partnership will utilize Immunai’s cutting-edge immune system mapping tools to enhance precision in immunology and oncology trials.

Teva soars with double-digit growth in Q3, raises annual forecast

06.11.24|Sophie Shulman

Strong sales of Austedo and Ajovy push Teva’s revenues above expectations, with the company forecasting up to $16.5 billion in 2024.

Teva to pay $450 million over Copaxone price inflation

11.10.24|Sophie Shulman

Settlement with the Department of Justice addresses price hikes from $17,000 to $85,000 per year for the multiple sclerosis drug.

Teva's vision 2025: Building on momentum for future market leadership

04.08.24|Sophie Shulman

Richard Francis’ strategic plan aims to transform Teva into a powerhouse of growth and innovation.

Teva posts impressive Q2 results, ups 2024 revenue forecast

31.07.24|Sophie Shulman

Strong sales of Austedo and Ajovy lead to double-digit growth for the Israeli pharma company.

How Monday overtook NICE and why Teva is on course to becoming Israel's highest-valued company

24.07.24|Sophie Shulman

While Wall Street transitions from growth stocks to value stocks, the balance of power among Israeli giants is also shifting. This reflects the speed at which the market punishes companies and rewards those leading growth processes, returning to profitability, or correctly identifying emerging fields.

Teva settles $750 million tax dispute with Israeli authorities

25.06.24|Sophie Shulman

The deal with the Israel Tax Authority resolves all pending litigation related to taxes payable for the years from 2008 to 2020

Teva shares continue to surge, climb to highest mark in more than five years on Q1 results

08.05.24|Sophie Shulman

AUSTEDO continues to be Teva's main growth engine and its flagship drug, with annual growth of 67% in sales

Why are Teva shares surging and how does it plan to keep it up

04.04.24|Uri Tel Tenne

Since the beginning of the year, Teva's shares have risen by about 36%, and are among the best performing stocks on the Tel Aviv Stock Exchange. Why is this happening and how is the company's CEO planning to build on the momentum?

Teva has sights on $12.2 billion Humira market after receiving FDA approval for arthritis injection

25.02.24|Meir Orbach

The Israeli pharma company and Iceland’s Alvotech announced that the SIMLANDI injection has been approved as an interchangeable biosimilar to Humira for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn’s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis

Teva CEO: "The company played not to lose, now we’ll play to win"

21.02.24|Sophie Shulman

Richard Francis' decision to focus on innovative drugs has boosted the stock by 40% since he took office. However, the high debt is still burdensome and the realization of the potential depends on the success of developments that are still in the laboratory

ריצ'רד פרנסיס מנכ"ל טבע החדש על רקע אתר חברת טבע בכפר סבא

Teva expects lower profits in 2024 despite a strong Q4 performance

31.01.24|Reuters

"We are gaining momentum, and now it's about executing as we did in 2023 in 2024," said CEO Richard Francis

Teva CEO: Israel’s production capacity has not been affected by the war

08.11.23|Sophie Shulman

The Israeli pharmaceutical company’s revenues grew by 7% in the last quarter to $3.9 billion, according to a report it recently published.

יונתן קולבר, מנהל שותף של ION מפעל טבע בכפר סבא

$300 million Teva bet: Will Norway's wealth fund and ION regret investing in the pharma giant?

11.09.23|Almog Azar

ION, which manages investments for the Norwegian wealth fund, began a buying spree of Teva shares at the beginning of the year